Johnson & Johnson reported long-term Phase III CARTITUDE-4 study results showing that a single infusion of Carvykti ...

"Johnson & Johnson’s CARVYKTI improves survival in multiple myeloma trial" was originally created and published by Clinical ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

More than 200 people were reported rescued from floodwaters in North Carolina following Helene’s torrential rains with more ...

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...

A benefit for local musician and worship pastor Chris Robbins will be held at the Friedhof Building Sunday, Sept. 29, from ...

Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead ...

Johnson & Johnson reports positive results for Talvey in combination with Darzalex Faspro, pomalidomide and Tecvayli in the ...

Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...